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Abstract Invasive lobular carcinoma of the breast is known
to produce intracellular mucin and has been recognized in
single-case reports to show extracellular mucin production,
as well. This latter morphology is not only rare but must also
be under- or misdiagnosed. The aim was to better characterize
this entity. Cases of lobular cancers demonstrating extracellu-
lar mucin formation were identified in a multi-institutional
effort and their clinical and morphologic features were
assessed. Immunohistochemistry was used to characterize
the E-cadherin-membrane complex, neuroendocrine differen-
tiation, and to some extent, mucin formation. All but one of
the eight cases occurred in postmenopausal patients.
Extracellular mucin production was present in 5 to 50% of
the tumour samples and rarely also appeared in nodal and
distant metastases. The tumours were completely E-cadherin
negative and showed cytoplasmic p120 positivity. The major-
ity (n = 6/8) was also completely negative for β-catenin, but
two tumours displayed focal β-catenin positivity in the mu-
cinous area. MUC1 andMUC2 expression was observed in all
and 7/8 tumours, respectively; neuroendocrine differentiation
was present in only one. Invasive lobular carcinoma with ex-
tracellular mucin formation is a rare morphologic variant of
lobular carcinoma prone to be misdiagnosed and warranting
further studies.
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Introduction
Invasive lobular carcinoma (ILC) is the most common special
type of breast carcinoma characterized by peculiar morpholo-
gy, molecular background, clinical manifestation, including
radiologic presentation and metastatic pattern. Besides classi-
cal ILC described by Foote and Stewart [1], several variant
forms have been reported in the literature, including solid [2],
signet ring cell [3], tubulolobular [4], alveolar [5], trabecular
[5], and pleomorphic [6–8] variants. ILC of mixed type con-
sists of a mixture of the classic type with one or some of the
other subtypes without quantitative requirement from the part
of the components [9, 10]. Variant patterns often present as
part of ILC mixed type, and their pure form is rather rare.
Current classifications define ILC with its morphological
features and include the loss of E-cadherin expression and al-
terations in other E-cadherin complex molecules like β-catenin
and p120-catenin as characteristic [10, 11]. The categorization
of lobular carcinoma as lobular on morphological grounds
alone is not always straight forward, and inter-observer varia-
tion has been described [12]. The recognition of different var-
iants of the disease can also pose difficulties. E-cadherin immu-
nohistochemistry (IHC) may aid in the distinction from other
tumour types [13], but requires also careful evaluation of the
staining and its context. Non-lobular carcinomas have also been
described to show diminished or lost E-cadherin expression
[14, 15], and aberrant E-cadherin expression has been a noticed
phenomenon in a subset of ILCs [16]. However, in non-lobular
carcinomas with reduced or lacking E-cadherin expression, the
integrity of the E-cadherin-membrane complex seems main-
tained as illustrated by the membranous expression of β- and
p120-catenins [17]. In contrast, aberrant expression of E-
cadherin seen in lobular carcinomas is associated with the loss
of membranous staining for other molecules of the E-cadherin-
membrane complex [18]. Therefore, the analysis of E-cadherin,
β-catenin, and p120-cateninmay help to better classify tumours
with non-obvious morphological features of ILC.
Some of the authors of this manuscript have encountered a
variant of ILC with extracellular mucin production (ILC-
ECMUC) partly reminiscent of mucinous carcinoma that has
not yet been included in the pattern classification of ILC [9–11].
A few previous single-case reports suggest that others had also
recognized this entity before [19–23]. A series of such cases has
been collected from archived routine and consultation material
of the members of the European Working Group for Breast
Screening Pathology in order to characterize this form of ILC.
Materials and methods
The authors have searched their files for identifying cases that
might probably represent ILC-ECMUC. Representative
formalin-fixed paraffin-embedded blocks from the material
used for the original diagnostic work-up were selected and
were analysed for the expression of the antigens highlighted
by the antibodies listed in Table 1. Whenever IHC was done at
the local laboratory either as a diagnostic aid or as a confirma-
tion of the case matching ILC-ECMUC, the results were taken
into account and IHC was not repeated. Whenever a stain was
missing from the panel, a formalin-fixed and paraffin-
embedded block or unstained slides were sent to the first au-
thor’s laboratory for IHC to be done. It ensues that the anti-
bodies used were not uniform as highlighted in Table 1. The
authors agreed that although there might be differences be-
tween the antibodies, in general practice, all of them are used
in the diagnostic setting and are suitable to make a diagnosis
based on the presence or absence of staining and the
localization/pattern of staining. Therefore, no attempt was
made to harmonize the clones used. In addition to IHC, peri-
odic acid Schiff (PAS) and PAS-Alcian blue stains (at pH 2.5)
were obtained from the cases.
For oestrogen and progesterone receptors (ER and PR), as
well as for human epidermal growth factor receptor 2 (HER2),
the American Society of Clinical Oncology/College of
American Pathologists recommendations were used for clas-
sifying the tumours as positive or negative [24, 25]. For other
immunostains, the pattern was considered diffuse when ≥50%
of the cells stained, and focal when <50% showed staining;
complete lack of staining was considered negative.
Multifocality was defined according to Tot, i.e. distinct inva-
sive tumour foci separated by any amount of uninvolved
breast tissue [26].
The ethical committee of Bács-Kiskun County Teaching
Hospital was consulted about this retrospective non-
interventional study and no objections were raised. The ap-
proval (no 1/16 10 26) included a waiver of an informed
consent in this study setting. As mandated by local regula-
tions, the data safety manager of Bács-Kiskun County
Teaching Hospital also approved the study, and the case from
Zurich was also covered by a local ethical approval of the
Canton Zurich.
Results
The present series includes eight ILC-ECMUCs seen between
1998 and 2016 and retrieved from seven European pathology
institutions. All but one of these tumours were diagnosed in
postmenopausal women, of whom five had no hormonal re-
placement therapy (HRT), whereas two had no information
available in this context. The mean age of the patients was
62.9 (range 45–75) years. The reported cancers were all pal-
pable at presentation, the mammographic appearance was
available for seven of them: five presented as masses
(spiculated or nodular, two associated with microcalcifications)
and two showed only architectural distortion. Seven tumours
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had a core needle biopsy preoperatively: three were originally
and/or preoperatively diagnosed as having a mucinous carcino-
ma component without the recognition that this represented
part of ILC (cases 1, 2, and 4); two had the diagnosis of lobular
carcinoma and no mucin production was visualized even in
retrospect (cases 5 and 8); and two were recognized as
representing ILC-ECMUC (cases 3 and 7). Some of the char-
acteristics of the tumours are summarized in Table 2.
Of the eight cases analysed, seven were from surgically
resected tumours, and the eighth was a core needle biopsy.
All tumours demonstrated areas of non-mucinous ILC and
five of the eight cases also included foci of classic lobular
Table 1 Antibodies used in the
series Clone Source Dilution Number of
cases
stained
ER 6F11 Leica/Novocastra, Newcastle, UK 1:50 4
1D5 Dako, Glostrup, Denmark 1:50 1
EP1 Dako, Glostrup, Denmark RTU 1
SP1 Roche/Ventana, Tucson, AZ RTU 2
PR Pgr312 Leica/Novocastra, Newcastle, UK 1:50–1:200 5
Pgr636 Dako, Glostrup, Denmark RTU 2
1E2 Roche/Ventana, Tucson, AZ RTU 1
HER2 4B5 Roche/Ventana, Tucson, AZ RTU 6
HercepTest Dako, Glostrup, Denmark RTU 1
Polyclonal
(A0485)
Dako, Glostrup, Denmark 1:300 1
E-cadherin 36B5 Leica/Novocastra, Newcastle, UK 1:40 4
36 Roche/Ventana, Tucson, AZ RTU 1
EP700Y Cell Marque, Rocklin, CA 1:200 1
HECD-1 Zymed/Invitrogen 1:200 1
NCH-38 Dako, Glostrup, Denmark RTU 1
Beta-catenin Clone 14 Histopathology, Pécs, Hungary 1:150 5
Clone 14 Roche/Ventana, Tucson, AZ RTU 1
Clone 14 BD Bioscience, San Jose, CA, USA 1:50 1
CAT-5H10 Zymed/Invitrogen 1:400 1
p120 98/pp120 Biocare, Concord, CA 1:150 6
Clone 98 BD Bioscience, San Jose, CA, USA 1:200–300 2
HMWCK 34beta-E12 Cell Marque, Rocklin, CA 1:300 1
Dako, Glostrup, Denmark RTU, 1:50,
1:250
6
MUC1 (EMA) E29 Biogenex, Fremont, CA 1:100 1
EPR1023 Biogenex, Fremont, CA RTU 4
MA552 Leica/Novocastra, Newcastle, UK 1:100 1
MA695 Leica/Novocastra, Newcastle, UK 1:50 1
MRQ17 Roche/Ventana, Tucson, AZ RTU 1
MUC2 MRQ18 Cell Marque, Rocklin, CA 1:200 5
Ccp58 Leica/Novocastra, Newcastle, UK 1:100 2
Ccp58 Scy Tec, Logan, UT, USA 1:10 1
Chromogranin LK2H10 Cell Marque, Rocklin, CA RTU 5
LK2H10-phe5 Thermo Fisher Scientific, Waltham,
MA
1:3000 1
DAK-A3 Dako, Glostrup, Denmark 1:50 1
Polyclonal
(A0430)
Dako, Glostrup, Denmark 1:800 1
Synaptophysin Polyclonal Cell Marque, Rocklin, CA RTU 1
MRQ40 Cell Marque, Rocklin, CA 1:200 1
27G12 Leica/Novocastra, Newcastle, UK RTU, 1:20 4
SP11 Roche/Ventana, Tucson, AZ RTU 1
DAK-SYNAP Dako, Glostrup, Denmark 1:50 1
CD56
(NCAM)
123C3.D5 Cell Marque, Rocklin, CA 1:50, 1:400 5
123C3 Roche/Ventana, Tucson, AZ RTU, 1:50 2
MRQ-42 Cell Marque, Rocklin, CA 1:500 1
Ki67 MIB 1 Dako, Glostrup, Denmark RTU, 1:100 7
Clone 30.09 Roche/Ventana, Tucson, AZ RTU 1
ER oestrogen receptor, EMA epithelial membrane antigen, HER2 human epidermal growth factor receptor 2,
HMWCK high-molecular weight cytokeratin, NCAM neural cell adhesion molecule, PR progesterone receptor,
RTU ready to use (prediluted)
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neoplasia (LN), a term with a meaning encompassing lobular
carcinoma in situ, atypical lobular hyperplasia, and ductal in-
volvement by the same type of neoplastic cells with or without
pagetoid spread [10]; a component of more pleomorphic LN
was identified in case 1. LN showed production of extracellu-
lar mucin in two cases (Fig. 1). The non-mucinous ILC com-
ponent was of the classical type in seven cases, along with
solid-type ILC in three cases, and there was only a solid com-
ponent in one case. Themucinous area represented about 10 to
70% of the tumour in resection specimens, and 5% of the core
biopsy, where it formed a single nodule of 0.6 mm in diameter.
In this latter case (case 7), neoadjuvant chemotherapy was
administered and mastectomy was performed afterwards.
The review of the mastectomy specimen showed no remain-
ing extracellular mucinous component, but had about 30% of
pleomorphic ILC component. Microscopic multifocality was
identified in three cases. Case 8 displayed a focal area of
necrosis.
Extracellular mucin production was seen either in the form
of relatively circumscribed single or multiple nodular areas
(7/8 cases) or was patchy with irregular borders through dif-
ferent areas of the tumour (1/8 cases) (Fig. 1a–c). One case
featured circumscribed foci of mucin production and smaller
areas with irregular lakes of this substance, and another case
had a nodular area of mucin production with partly irregular
borders. The mucinous component stained with PAS and was
blue with the combined PAS-Alcian blue stain.
Tumour cells in the mucinous area were often arranged in
clusters or even simple or cribriform gland-like structures,
although cellular cohesion (in contrast to glands in mucinous
carcinoma) was not obvious and some dissociated single cells
were generally present (Fig. 2). One case showed no cluster-
ing of the cells, although some Indian filing, a feature typical
of classical lobular carcinoma was identified in it (Fig. 2a).
The cells displayed moderate nuclear pleomorphism. Higher-
grade nuclei were identified only in a minor focus of LN in
case 1 and in about 30% of the non-mucinous part in the
mastectomy specimen of case 7, in which the mucinous com-
ponent was present only in the core needle biopsy. Local re-
currence of case 4 also displayed pleomorphic features.
Signet ring cells (SRC), as signs of intracellular mucin
formation were seen in all cases, but were generally scattered
and low in numbers, although they could be readily identified
in some cases. SRCs were seen in more abundance outside of
the mucinous area of case 3 (Fig. 2f). The highest number of
SRCs was seen in the metachronous omental metastasis of
case 2; the primary tumour also had some SRCs, but these
did not represent a characteristic feature of the tumour.
Axillary lymph node metastases were observed in five pa-
tients; only one showed areas of extracellular mucin produc-
tion, in keeping with the lobular mixed phenotype; the others
demonstrated non-mucinous ILC phenotype. The two local
recurrences were evaluated by histology and were devoid of
extracellular mucin on review too. Of the two distant metas-
tases occurring in the course of the follow-up, only one was
examined by microscopy, and displayed abundant extracellu-
lar mucin and high numbers of SRCs (Fig. 1f). The autopsy
material of case 2 was not available for review.
All tumours including the ILC-ECMUC areas were nega-
tive for E-cadherin and demonstrated cytoplasmic p120 caten-
in staining. Membranous β-catenin staining was completely
absent from six tumours, and was partially present in two
(Fig. 3). This involved the mucinous component and ranged
from focal partial membranous or complete circumferential
staining of a minority of cells in areas of lumen formation
(i.e. glandular differentiation) (Fig. 3d) to nearly complete,
diffuse, dominantly circumferential but sometimes only par-
tial membranous or lacking (Fig. 3e). Moreover, similar β-
catenin partial staining was also observed in the solid compo-
nent of case 4, but was definitely absent from the classic type
non-mucinous ILC of the same case (Fig. 3f). High-molecular
weight cytokeratin (HMWCK) staining seen in many lobular
carcinomas [27], was obtained in seven cases and was positive
in four. For what concerns neuroendocrine differentiation, all
tumours were negative for CD56, and all but one tumour were
negative for chromogranin A and synaptophysin. All cases
showed cytoplasmic positivity for MUC1 and 7/8 cases
showed MUC2 positivity as well, which was generally more
expressed in the mucinous area. All tumours were ER positive
(ranging from 60 to 100%). PR positivity was inferior to 1% in
one case, of low percentage (5%) in two cases, and the rest of
t h e t umou r s d i s p l a y ed 10 t o 90% po s i t i v i t y.
Immunohistochemistry for HER2 was positive (3+) in one
case and was 1+ or 2+ in two cases which were non-
amplified with fluorescent in situ hybridization. The Ki-67
index of the tumours ranged between 7 and 40%, and was
generally somewhat lower in the mucinous area (Table 2).
The surgical treatment consisted ofmastectomy in six cases
and breast conserving surgery in two. Four patients were
staged with sentinel lymph node biopsy only, and four had
axillary lymph node dissection either without or following
sentinel lymphadenectomy. Adjuvant radiotherapy was given
or for recently diagnosed cases is planned to be given to seven
patients. Aromatase inhibitors were/are part of the treatment
for four patients, whereas chemotherapy was given to four
patients, one received the treatment in the neoadjuvant setting.
One patient having a HER2 overexpressing tumour also re-
ceived trastuzumab for 1 year along with letrozole.
Since three cases were diagnosed in 2015–2016 and their
uneventful follow-up of less than 12 months is not meaning-
ful, only the data of the five remaining patients with longer
follow-up (median 29 months, range = 15–68 months) are
considered here. Three of them experienced recurrences: one
local, 68 months after initial diagnosis; one peritoneal
39 months after diagnosis and finally, one local and distant
(liver, bones and brain) 15 months after discovery and initial
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Fig. 1 Mucinous areas in lobular
carcinomas with extracellular
mucin production and its
metastases. Uninodular (a HE,
×5, case 3); multinodular (b HE,
×5, case 6) and non-
circumscribed (cHE, ×20, case 1)
mucinous areas. Note the lobular
neoplasia in the upper left corner
(c). d Lobular neoplasia with
extracellular mucin production
(HE, ×40, case 1). e Lymph node
metastasis with mucinous
component (HE, ×6, case 1); f
Pure mucinous distant metastasis
(HE, ×40, case 2).
Fig. 2 Morphological patterns of
ILC-ECMUC. a Paucicellular
pattern with discohesive cells
sometimes arranged in single-cell
lines (asterisk) (×20, case 3). b
Pseudocribriform or
pseudoglandular structures with
mucin filled lumina; inset single
tubule-like lumen (HE, ×40, case
4; inset beta-catenin, ×72, case 8).
c, d Solid sheet-like clusters of
cells reminiscent of lobular
carcinoma in situ. Some cells
contain intracellular mucin as
highlighted by Alcian blue
(arrows). (HE (c) and Alcian blue
(d), ×40, case 4). e Groups of cell
floating in pools of mucin,
reminiscent of classical mucinous
carcinoma; some of the cells
contain intracytoplasmic vacuoles
(HE, ×72, case 2). e Non-
mucinous component
demonstrating higher number of
signet ring cells (HE, ×20, case 3)
8 Virchows Arch (2017) 471:3–12
treatment. The latter two patients died of their disease 40 and
21 months after recognition of the tumours, respectively.
Discussion
The cases described here correspond to the entity previously
reported in single-case reports as ILC-ECMUC [19–23].
Although the areas of the tumours demonstrating lakes of
extracellular mucin could be classified as mucinous on the
basis of the Bneoplastic cells floating within extracellular
mucins^ definition [11], and could also be labelled as mucin-
ous carcinoma with lobular features, the authors all preferred
the alternative labelling of these tumours as ILC-ECMUC or
ILC with mucinous features, in keeping with earlier single-
case reports [19–23]. The rationale for this preference in ter-
minology includes a classical ILC component present around
the mucinous area in most cases, the presence of associated
LN, a precursor lesion, in most cases, and the fact that cells in
the mucinous area, whether clustered, lumen forming or not,
also showed alterations of the E-cadherin-membrane complex
characteristic of lobular carcinomas. It is recognized that some
ILCs may show formation of rare glandular structures, which
are E-cadherin negative (Fig. 2b) and this should not refute the
diagnosis of an ILC [18], and more complex lumen-like struc-
tures (Fig. 2b) were also considered analogously, i.e. not re-
futing ILC by being E-cadherin negative. In cases of aberrant
E-cadherin staining, p120 and β-catenin are recommended as
additional IHC stains that may clarify the histological type
[18]. Aberrant β-catenin membranous stain in the lack of
membranous expression of E-cadherin and p120 has not been
studied, but the latter stains are in keeping with lack of integ-
rity of the E-cadherin-membrane complex.
Acknowledging ILC-ECMUC as a distinct variant of ILC,
examples demonstrating this phenotype along with classic
ILC or other variants (e.g. the solid) could be categorized as
ILC mixed type. Reviewing the case reports [19–23] and the
present series suggests that these tumours always included
smaller or larger areas of non-mucinous ILC, generally of
Fig. 3 Two cases with discordant
lobular carcinoma
immunohistochemistry. a–d
Approximately same area of case
6 with a H&E, b E-cadherin, c
p120 catenin and d beta-catenin
stains (All ×40 originally; insets
×70). While E-cadherin is
negative in the mucinous area,
and p120-catenin shows a
cytoplasmic staining in keeping
with the diagnosis of lobular
carcinoma, beta-catenin is focally
and weakly positive in the
mucinous area (not in the
surrounding classic lobular
carcinoma—not shown). e–h
Case 4, beta-catenin more
diffusely and strongly but still not
completely staining the mucinous
part (e) and being completely
negative in the surrounding
classic type (f, both ×40). The E-
cadherin staining (g, ×20) is
negative in both components,
whereas the p120-catenin (h,
×10) staining is cytoplasmic as
expected in lobular carcinomas
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the classical, sometimes additionally of the solid type. Of
course, this does not exclude the possibility of a pure ILC-
ECMUC. As can be expected in case of mixed type tumours,
heterogeneity is also present in their metastases, as exempli-
fied by only 1/5 of node-positive ILC-ECMUCs showing an
area of extracellular mucin formation in the lymph nodes.
Only two of the three previous case reports give relevant de-
tails in respect of nodal involvement [19–22], and only one of
the cases showed the features of ILC-ECMUC in nodal me-
tastases [22]. Case 2 of the present series deserves special
attention: it had 11/13 lymph nodes involved, and none of
these showed mucinous features, whereas the only slide of
an omental metachronous distant metastasis developing
39 months after primary surgical treatment showed a pure
ILC-ECMUC with relatively high numbers of SRCs
(Fig. 1f). The other two cases with local failures showed no
extracellular mucin formation in the recurrence.
The low yield of the search suggests that this is a rare
morphologica l en t i ty, a l though i t mus t a l so be
underdiagnosed, as some earlier cases were primarily diag-
nosed as (mixed) mucinous (MBC) or ductal (no special type)
carcinomas with mucin formation. Owing to the fact that a
core needle biopsy may sample the mucinous part only, where
the cells are sometimes clustered and lumen forming, a low
power examination may yield a Bfalse^ diagnosis of MBC.
Looking for radiologic correlation in a multidisciplinary set-
ting may help in avoiding such misdiagnoses, as classical
MBCs are typically circumscribed, whereas ILCs are not un-
commonly seen as architectural distortions or spiculated
masses, as some of the present series, or a previous case report
[23]. Hitting the non-mucinous area may obviously result in
the diagnosis of ILC without extracellular mucin formation, as
was the case in two instances of the present series.
Previous reports have all identified SRCs in ILC-ECMUC
in varying amounts as an evidence of intracellular mucin ac-
cumulation. Both these cells and extracellular mucin showed
PAS, mucicarmin and Alcian blue staining when investigated
for these stains. Likewise, SRCs were also seen in all cases of
the present series, ranging from rare to strikingly evident, al-
though the area with most SRCs in a primary tumour was
outside of the mucinous area (Fig. 2f). In keeping with previ-
ous reports, the extracellular mucin was positive with Alcian
blue in all cases and showed strong or weaker PAS positivity
as well, similarly to varying amounts of intracellular mucin. It
must be noted that in their description of five SRC carcinomas
as variants of ILC, Steinbrecher and Silverberg illustrate a
case (number 3 in their series) with extracellular mucin for-
mation without paying much attention to this feature they
Fig. 4 Differential diagnostic
considerations. a, b Mucinous
carcinoma, type B by Capella
demonstrating neuroendocrine
differentiation and membranous
staining with the E-cadherin-
membrane complex proteins. (a
H&E ×40, Inset Chromogranin A
×40; b E-cadherin ×40, Inset
×70). c, d Solid papillary
carcinoma with area of
extracellular mucin formation (c
H&E ×15, Inset synaptophysin
×40; d p120 ×15, Inset ×70). e, f
Composite tumour with
mucinous carcinoma (left) and
lobular carcinoma (right) (e H&E
×20, Inset ×40; f β-catenin ×20,
Inset ×40)
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describe [3]. Worth mentioning, Gad and Azzopardi had de-
scribed (intracellular) mucin production of lobular carcinomas
a year earlier [28].
The mucin composition of a case of ILC-ECMUC was
analysed in details earlier. The case was found to show posi-
tivity for MUC1, but was negative for MUC2, MUC4,
MUC5AC and MUC6 [20]. Our series demonstrated positiv-
ity for the secretory mucin MUC2 in 7/8 cases.
Neuroendocrine differentiation can occur in several breast
cancer types including LN [29] and has been often seen asso-
ciated with (intracellular or extracellular) mucin production
[30]. It was present in one case of the present series.
Neuroendocrine markers were investigated in only two previ-
ous cases reported and were negative [21, 22]. This may be of
importance in the differential diagnosis of this tumour sub-
type, since mucinous carcinoma of type B after Capella often
shows neuroendocrine differentiation [31] along with mem-
branous expression of E-cadherin and other members of the E-
cadherin-membrane complex (Fig. 4a, b).
Another tumour that may come into the differential diag-
nosis is solid papillary carcinoma, which also often features
neuroendocrine differentiation and can be associated with mu-
cin production and even mucinous carcinoma [32]. However,
this tumour also shows a non-lobular phenotype as concerns
the E-cadherin-membrane complex (Fig. 4c, d). Sometimes
mixed ILC and MBC may also occur, as a combination of
the two distinct histological types (Fig. 4e, f). The evaluation
of E-cadherin staining should also help in distinguishing these
two distinct phenotypes. Due to their mucoid/myxoid stroma,
matrix-producing metaplastic carcinomas [33] and polymor-
phous mammary adenocarcinomas [34] may also enter the
differential diagnosis, especially as they may show lacking
or altered E-cadherin expression [34, 35], and polymophous
carcinoma may also mimic the Indian-filing pattern of classic
ILC [34, 36]. However, both these latter tumours are typically
ER-negative and have other features distinguishing them from
ILC [10, 11]. In the metastatic setting, mucin-producing tu-
mours of other organs come also into consideration, and SRC
carcinomas (most often of gastric origin) must also be thought
about, since they share features with ILC-ECMUC, including
the lack of E-cadherin staining.
The reasoning described at the beginning of the discussion
led us and others to classify the morphology seen in the cases
of the present series as representing ILC of mixed type, with a
component forming extracellular mucin (ILC-ECMUC). As
the production of extracellular mucin is rare in lobular carci-
nomas (which are generally known to produce intracellular
mucin), we have included all cases demonstrating this feature
into the category of ILC-ECMUC, independently of the pro-
portion of the tumour showing it. We believe that recognising
the entity of ILC-ECMUC is important because of its mimic
of mucinous carcinoma and other mucin-producing carcino-
mas which may have completely different diagnostic,
therapeutic and prognostic implications. It is impossible to
draw conclusions about the natural history of these tumours
due to the low number of cases and to the presence of a sub-
stantial to dominant non-mucin-forming component in all
cases seen to date. Therefore, we must restrict the conclusions
to the morphology of these cases which might be
misperceived or misdiagnosed as mucinous carcinomas of
pure or mixed type both in biopsies of the primary tumour
or its metastases. Recognition of this rare but also
underdiagnosed morphology/entity and the availability of a
cell line model [37] may lead to a better understanding of its
formation and biology.
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